https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-18 / Expert Opin Biol Ther 2015 Jan;15(1):79-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-18 / Expert Opin Biol Ther 2015 Jan;15(1):79-942014-10-18 00:00:002019-02-15 08:47:21Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-26 / Cancer Invest. 2014 Nov;32(9):451-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-26 / Cancer Invest. 2014 Nov;32(9):451-72014-09-26 00:00:002019-07-01 06:51:38Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-25 / Cell Death Dis 2014 Sep;5:e1426
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-25 / Cell Death Dis 2014 Sep;5:e14262014-09-25 00:00:002014-09-25 00:00:00MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-19 / Int J Cancer 2015 Mar;136(5):E313-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-19 / Int J Cancer 2015 Mar;136(5):E313-252014-09-19 00:00:002022-09-29 14:01:04Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-09-12 / PLoS ONE 2014;9(9):e107173
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-09-12 / PLoS ONE 2014;9(9):e1071732014-09-12 00:00:002019-02-15 08:47:33Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-27 / Biomed Res Int 2014;2014:386470
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-27 / Biomed Res Int 2014;2014:3864702014-08-27 00:00:002019-02-15 09:00:13Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-08-05 / Int. J. Cancer 2015 Feb;136(4):E74-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-08-05 / Int. J. Cancer 2015 Feb;136(4):E74-842014-08-05 00:00:002019-02-15 08:46:15Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 3069)2014-06-01 12:06:002019-07-17 12:06:29Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2005)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2005)2014-06-01 11:49:162019-07-17 11:49:36A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-31 / J Clin Oncol 32:5s, 2014 (suppl; abstr 2087)2014-05-31 11:58:292019-07-17 11:58:59Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy.
